Jeffrey Burbank - NxStage Medical Founder, CEO and Director
CEO
Mr. Jeffrey H. Burbank is Chief Executive Officer, Director of NxStage Medical, Inc. Mr. Burbank has served in these positions since he founded the company in December 1998. Mr. Burbank has over 30 years of indepth management experience with companies developing, marketing and manufacturing products for ESRD patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporationrationration, the evolution of the product line, and into services. Prior to founding NxStage, Mr. Burbank cofounded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the Board. He gained significant renal industry experience during his nine years in the Renal Division at Gambro, Inc., a medical technology company, with his last position as Director of Marketing and Advanced Technologies. During his career he was an inventor on over 50 U.S. patents for medical devices since 2011.
| Age | 54 |
| Tenure | 13 years |
| Phone | 978 687-4700 |
| Web | www.nxstage.com |
NxStage Medical Management Efficiency
NxStage Medical's management efficiency ratios could be used to measure how well NxStage Medical manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 13.31 M in liabilities with Debt to Equity (D/E) ratio of 5.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. NxStage Medical has a current ratio of 3.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist NxStage Medical until it has trouble settling it off, either with new capital or with free cash flow. So, NxStage Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NxStage Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NxStage to invest in growth at high rates of return. When we think about NxStage Medical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 12 records | CEO Age | ||
| Yaron Ravkaie | Radcom | 48 | |
| Lei Chen | Pinduoduo | 44 | |
| Charles Morrison | Wingstop | 49 | |
| Bernard Acoca | El Pollo Loco | 49 | |
| Jiazhen Zhao | Pinduoduo | 40 | |
| Emil Brolick | The Wendys Co | 68 | |
| Todd Penegor | The Wendys Co | 59 | |
| David Ripstein | Radcom | 47 | |
| Stephen Sather | El Pollo Loco | 68 | |
| Kirk Tanner | The Wendys Co | 55 | |
| Michael Skipworth | Wingstop | 46 | |
| Brett Schulman | CAVA Group | 51 | |
Management Performance
| Return On Equity | -0.0655 | |||
| Return On Asset | -4.0E-4 |
NxStage Medical Leadership Team
Elected by the shareholders, the NxStage Medical's board of directors comprises two types of representatives: NxStage Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NxStage. The board's role is to monitor NxStage Medical's management team and ensure that shareholders' interests are well served. NxStage Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NxStage Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Heyward Donigan, Director | ||
| Norit Sion, Director | ||
| Jeffrey Burbank, Founder, CEO and Director | ||
| Moshe Gur, Vice President of Installation and Communications | ||
| Shlomo Bason, External Director | ||
| Joseph Turk, President | ||
| Daniel Giannini, Independent Director | ||
| Barry Straube, Independent Director | ||
| Winifred Swan, Senior Vice President General Counsel, Secretary | ||
| Jean Mixer, Director | ||
| Craig Moore, Independent Director | ||
| Shlomo Basson, External Director | ||
| Omry Shahar, Vice President of Infrastructure | ||
| Robert Brown, President of Nxstage Kidney Care | ||
| Israel Tchetchik, Director | ||
| Daniel Sztern, External Director | ||
| Reid Perper, Independent Director | ||
| Earl Lewis, Independent Director | ||
| Matthew Towse, CFO and Sr. VP | ||
| Guy Israely, Chairman of the Board, CEO | ||
| Galit Lior, Controller | ||
| Robert Funari, Non-Executive Chairman of the Board | ||
| Yoav Levin, Vice President of Sales | ||
| Sarit Cohen, CFO | ||
| Dana Erlich, Internal Auditor | ||
| James Peters, Director |
NxStage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NxStage Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0655 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 1.89 B | |||
| Shares Outstanding | 66.68 M | |||
| Shares Owned By Insiders | 2.10 % | |||
| Shares Owned By Institutions | 91.91 % | |||
| Number Of Shares Shorted | 5.3 M | |||
| Price To Earning | (354.68) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NxStage Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NxStage Medical's short interest history, or implied volatility extrapolated from NxStage Medical options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in NxStage Stock
If you are still planning to invest in NxStage Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NxStage Medical's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |